摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol | 1374524-68-1

中文名称
——
中文别名
——
英文名称
(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol
英文别名
ME-344;Me-344
(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol化学式
CAS
1374524-68-1
化学式
C22H20O4
mdl
——
分子量
348.398
InChiKey
QVCAATSEPLQVBX-FPOVZHCZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    69.9
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    7-(tert-butyldimethylsilyloxy)-3-(4-(tert-butyldimethylsilyloxy)phenyl)-4-(4-methoxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-4-ol 在 [10%-Pd/Al2O3] 、 氢溴酸氢气对甲苯磺酸溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 13.0h, 生成 (3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol
    参考文献:
    名称:
    [EN] COMBINATION THERAPIES
    [FR] POLYTHÉRAPIES
    摘要:
    本文提供了一种治疗癌症的组合物、方法和试剂盒,包括线粒体抑制剂和Bcl-2抑制剂。
    公开号:
    WO2021252776A1
点击查看最新优质反应信息

文献信息

  • [EN] ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'ISOFLAVONOÏDES ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
    申请人:MARSHALL EDWARDS INC
    公开号:WO2012061409A1
    公开(公告)日:2012-05-10
    Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    本发明提供了一种含有至少一种异黄酮类化合物的制药组合物。本发明还提供了通过给予该组合物来治疗癌症、增加癌细胞敏感性和诱导癌细胞凋亡的方法。
  • COMBINATORY TREATMENT FOR LYMPHOMA
    申请人:Université de Paris
    公开号:EP3892267A1
    公开(公告)日:2021-10-13
    The invention relates to the field of medicine and more particularly to novel combinations and combinatory treatments useful for treating lymphoma. More particularly, the invention thus relates to a combination comprising at least one inhibitor of glutamine metabolism or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof and at least one inhibitor of mitochondrial electron transport chain or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof, for its use in the treatment or the prevention of a lymphoma in a subject in need thereof.
    本发明涉及医学领域,尤其涉及治疗淋巴瘤的新型组合物和联合疗法。更具体地说,本发明涉及一种组合物,该组合物包含至少一种谷氨酰胺代谢抑制剂或其药学上可接受的盐、原药、衍生物或缓释制剂,以及至少一种线粒体电子传递链抑制剂或其药学上可接受的盐、原药、衍生物或缓释制剂,用于治疗或预防有需要的受试者的淋巴瘤。
  • Isoflavonoid compositions and methods for the treatment of cancer
    申请人:MEI PHARMA, INC.
    公开号:US10369132B2
    公开(公告)日:2019-08-06
    Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    本文提供了一种药物组合物,该组合物由异黄酮衍生物和环糊精组成。本文还提供了通过施用此类组合物治疗癌症、敏化癌细胞和诱导癌细胞凋亡的方法。具体而言,本文提供了静脉注射组合物和疗法。
  • ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
    申请人:MEI Pharma, Inc.
    公开号:EP2635273B1
    公开(公告)日:2020-01-08
  • ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
    申请人:Jeoffreys George
    公开号:US20140234295A1
    公开(公告)日:2014-08-21
    Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
查看更多